Skip to content
Search

Latest Stories

Pharmacy regulator must remove potential barriers while managing FtP concerns, says RPS

The Royal Pharmaceutical Society has welcomed the pharmacy regulator's ambition to better understand why a disproportionately higher number of concerns about black, Asian and minority ethnic professionals are made.

In its response its response to the General Pharmaceutical Council’s consultation on its future strategy for managing fitness to practise (FtP) concerns about pharmacy professionals, the RPS said "inclusion and diversity" should be given "greater prominence".


"The RPS is committed to making inclusion and diversity (I&D) central to the way we champion the pharmacy profession. We welcome the aim of addressing challenges in how the GPhC considers equality, diversity and inclusion. We accept that this is considered as part of strategic aim... However we believe it warrants greater prominence and should be included as a stand-alone strategic aim."

The GPhC’s fitness to practice strategy prepared during the Covid-19 pandemic aims to protect community pharmacists and the public through better practices. The strategy aims to give patients and the public better protection while being fair to pharmacy professionals.

Commenting on the GPhC consultation which concluded last week (Jan 22), the RPS president Sandra Gidley said: “We very much welcome the consultation, which aims to ensure patients are protected whilst promoting and encouraging a learning culture that allows pharmacy professionals to deal with any concerns and go back to practising in appropriate circumstances.”

With the consultation, the GPhC aims to make sure that its FtP work remains relevant and that it continues to deliver its main objective of protecting the public. It also aims to take quick action to protect patients when that is needed. Additionally, the consultation aims to minimise potential biases against BAME professionals.

“Registrants from Black, Asian and Minority Ethnic communities are currently disproportionately represented in FtP cases. By talking to our membership and the wider profession, including our ABCD group, we have identified potential barriers for people with protected characteristics and suggested measures to address any inequalities and bias within decision making. We would like to see further transparency and details from the GPhC as to how they are working to remove potential barriers,” the RPS president added.

In its ambition to minimise and deal with the risk of potential biases, the GPhC will be providing training to all FtP decision makers on unconscious bias.

“RPS members told us the length of time some fitness to practice cases take is a huge burden and needs to be reduced. When registrants are investigated, whether formally or informally, there are adverse implications for their careers, reputation and wellbeing. We are pleased to see an emphasis on improving this. We’d also like to see greater prominence placed on this and on the mental health and wellbeing of those involved," Gidley said.

“We are pleased with the person-centred approach which, when applied, will offer greater support for everyone involved in FtP cases. We also support the aim of promoting reflection and learning through the use of several, more flexible, outcomes such as reflective pieces and mediation. However, more detail is needed on these proposals.”

More For You

Cargo plane unloading pharmaceuticals at US airport amid tariff concerns and stockpiling

Imports jumped in particular from Ireland, the top drug exporter to the US

Pic credit: iStock

Pharma imports to US surged in March as drugmakers look to avoid tariffs

Pharmaceutical imports to the US surged in March as drugmakers stocked up ahead of potential US tariffs on their products, which have historically been exempt from such fees.

Total imports of pharmaceutical products exceeded $50 billion in the month - the equivalent of 20 per cent of all pharmaceutical imports in 2024, according to data from a U.S. Commerce Department report on Tuesday.

Keep ReadingShow less
Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less